Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1341-1347

  Saad, F ^a   Brown, J E ^b   Van Poznak, C ^c   Ibrahim, T ^d   Stemmer, S M ^e   Stopeck, A T ^f   Diel, I J ^g   Takahashi, S ^h   Shore, N ⁱ   Henry, D H ^j   Barrios, C H ^k   Facon, T ^l   Senecal, F ^m   Fizazi, K ⁿ   Zhou, L ^o   Daniels, A ^o   Carriere P ^o   Dansey, R ^o  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e RABIN MEDICAL CENTER   (Israel)

^f UNIVERSITY OF ARIZONA   (United States)

^g Institute for Gynecologic Oncology   (Germany)

^h CANCER INSTITUTE HOSPITAL   (Japan)

ⁱ Carolina Urologic Research   (United States)

^j PENNSYLVANIA HOSPITAL   (United States)

^k PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m Northwest Medical Specialties   (United States)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o AMGEN INC   (United States)

more..

Author keywords

Bone metastases; Denosumab; Osteonecrosis of the jaw; Zoledronic acid

Indexed keywords

ANTIBIOTIC AGENT; DENOSUMAB; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; JAW PAIN; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MOUTH INFECTION; MYELOMA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; TOOTH EXTRACTION; TREATMENT DURATION;

EID: 84860467736     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr435     Document Type: Article

References (41)

1. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587.
2. Cafro AM, Barbarano LA, Andriani A et al. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience. Blood (ASH Annual Meeting Abstracts) 2005; 106: (Abstr 5152).
3. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968-971.
4. Dimopoulos MA, Kastritis E, Moulopoulos LA et al. The incidence of osteonecrosis of the jaw (ONJ) in patients with multiple myeloma who receive biphosphonates depends on the type of biphosphonate. Blood (ASH Annual Meeting Abstracts) 2005; 106: (Abstr 637).
5. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
6. Pozzi S, Marcheselli R, Sacchi S et al. Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood (ASH Annual Meeting Abstracts) 2005; 106: (Abstr 5057).
7. Tosi P, Zamagni E, Cangini D et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood (ASH Annual Meeting Abstracts) 2005; 106: (Abstr 3461).
8. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134: 620-623.
9. Aragon-Ching JB, Ning YM, Chen CC et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009; 27: 221-226.
10. Migliorati CA, Woo SB, Hewson I et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010; 18: 1099-1106.
11. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.
12. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.
13. European Medicines Agency. CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw. London: EMA/CHMP. 2011; http://www.ema. europa.eu/docs/en_GB/document_library/Other/2010/01/WC500051383.pdf (12 April 2011, date last accessed).
14. Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945-952.
15. Hoff AO, Toth BB, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006; 24(18s): 8528.
16. Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 1650-1654.
17. Bagan JV, Jimenez Y, Murillo J et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006; 42: 327-329.
18. Jadu F, Lee L, Pharoah M et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18: 2015-2019.
19. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 2010; 122: 189-191.
20. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.
21. King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008; 28: 667-677.
22. Cavanna L, Berte R, Arcari A et al. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 2007; 18: 417-422.
23. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575.
24. Mashiba T, Mori S, Burr DB et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23 (Suppl): 36-42.
25. Fizazi K, Carducci M, Smith M et al. A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer. Lancet 2011; 377: 813-822.
26. Henry DH, Costa L, Goldwasser F et al. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
27. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
28. Department of Health and Human Services, Food and Drug Administration, Oncologic Drugs Advisory Committee. Gaithersburg, MD: Department of Health and Human Services, Food and Drug Administration. 2011; http://www.fda.gov/ohrms/ dockets/ac/cder05.html#OncologicDrugs (1 April 2011, date last accessed).
29. Cleeland C. Pain assessment in cancer. In Osoba D (ed): Effect of Cancer on Quality of Life. Boca Raton, FL: CRC Press 1991; 293-305.
30. Dmitrienko A, Molenberghs G, Chuang-Stein C, Offen W. Analysis of Clinical Trials Using SAS: A Practical Guide. Cary, NC: SAS Institute 2005.
31. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
32. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
33. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.
34. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-120.
35. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137-145.
36. Guarneri V, Miles D, Robert N et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188.
37. Bekker PJ, Holloway DL, Rasmussen AS et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066.
38. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007; 119 (Suppl 2): S150-S162.
39. American Dental Association. Report of the Council on Scientific Affairs: Dental Management of Patients Receiving Oral Bisphosphonate Therapy-Expert Panel Recommendations. 2011; http://www.ada.org/sections/professionalResources/ pdfs/topics_osteonecrosis_bisphosphonate_report.pdf (1 April 2011, date last accessed).
40. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 2009; 140: 864-875.
41. Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw-a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg 2011; 49: 251-257.